StockNews.com assumed coverage on shares of Nymox Pharmaceutical (NASDAQ:NYMX – Get Rating) in a report published on Sunday morning. The firm issued a sell rating on the biopharmaceutical company's stock.
Nymox Pharmaceutical Stock Performance
Shares of NASDAQ NYMX opened at $0.42 on Friday. Nymox Pharmaceutical has a fifty-two week low of $0.19 and a fifty-two week high of $2.10. The company has a market cap of $37.57 million, a PE ratio of -4.15 and a beta of 0.62. The business has a 50-day simple moving average of $0.36 and a two-hundred day simple moving average of $0.38.
Get Nymox Pharmaceutical alerts:Nymox Pharmaceutical (NASDAQ:NYMX – Get Rating) last issued its quarterly earnings results on Monday, November 14th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter.
Institutional Trading of Nymox Pharmaceutical
A hedge fund recently bought a new stake in Nymox Pharmaceutical stock. Citigroup Inc. bought a new position in shares of Nymox Pharmaceutical Co. (NASDAQ:NYMX – Get Rating) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 109,079 shares of the biopharmaceutical company's stock, valued at approximately $137,000. Citigroup Inc. owned approximately 0.12% of Nymox Pharmaceutical at the end of the most recent quarter. 0.78% of the stock is currently owned by hedge funds and other institutional investors.About Nymox Pharmaceutical
(Get Rating)
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia, and Phase II clinical trials for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma.
Featured Stories
- Get a free copy of the StockNews.com research report on Nymox Pharmaceutical (NYMX)
- Why Hershey Is a Sweet Recession Stock
- Will Amazon Stock Be Delivering for Investors in 2023?
- The Analysts Shift Trucking Sentiment Back into Forward
- The Institutions Book A Flight With Boeing
- 2 Biotechs Making Waves With A Single Product in their Pipeline
Receive News & Ratings for Nymox Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nymox Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.